<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306162</url>
  </required_header>
  <id_info>
    <org_study_id>1160.112</org_study_id>
    <secondary_id>2010-024009-11</secondary_id>
    <nct_id>NCT01306162</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects</brief_title>
  <official_title>Relative Bioavailability of a Single Dose of 150 mg Dabigatran Etexilate (Capsule) When Administered Alone or in Combination With a Single Dose of 400 mg Dronedarone Tablet) or in Combination With 400 mg Bid Dronedarone (Tablet) at Steady State in Healthy Male and Female Volunteers (an Open Label, Randomised, Four-sequence, Two Period Cross-over, Phase I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the relative bioavailability of a single dose of
      dabigatran after concomitant multiple oral administration of dronedarone with the aim to
      investigate whether and to what extent the P-gp inhibitor dronedarone affects pharmacokinetic
      parameters of dabigatran when administered to healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)</measure>
    <time_frame>1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
    <description>Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Dabigatran: Maximum Measured Concentration (Cmax)</measure>
    <time_frame>1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
    <description>Maximum measured concentration of total dabigatran in plasma, per period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Free Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)</measure>
    <time_frame>1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
    <description>Area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Dabigatran: Maximum Measured Concentration (Cmax)</measure>
    <time_frame>1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
    <description>Maximum measured concentration of free dabigatran in plasma, per period.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A: Dabigatran alone (Reference)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule, oral administration with 240 mL water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Dabigatran plus Dronedarone (Test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule and Tablets, oral administration with 240 mL water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Dabigatran plus Dronedarone (Test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule and Tablets, oral administration with 240 mL water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D: Dabigatran plus Dronedarone (Test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule and Tablets, oral administration with 240 mL water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E: Dabigatran plus Dronedarone (Test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule and Tablets, oral administration with 240 mL water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate plus dronedarone</intervention_name>
    <description>dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose</description>
    <arm_group_label>B: Dabigatran plus Dronedarone (Test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>150 mg as single dose</description>
    <arm_group_label>A: Dabigatran alone (Reference)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate plus dronedarone</intervention_name>
    <description>dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)</description>
    <arm_group_label>C: Dabigatran plus Dronedarone (Test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate plus dronedarone</intervention_name>
    <description>dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid</description>
    <arm_group_label>D: Dabigatran plus Dronedarone (Test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate plus dronedarone</intervention_name>
    <description>dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)</description>
    <arm_group_label>E: Dabigatran plus Dronedarone (Test)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Healthy male and female subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.112.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2011</study_first_posted>
  <results_first_submitted>May 23, 2012</results_first_submitted>
  <results_first_submitted_qc>June 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 14, 2012</results_first_posted>
  <last_update_submitted>June 3, 2014</last_update_submitted>
  <last_update_submitted_qc>June 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In this crossover study, subjects were randomly assigned to one of the 4 sequences, but with 5 treatments. In general terms ABDE,ACED,BDEA,CEDA. There were four subjects in Trt E who took Dronedarone mistakenly in place of Dabigatran. These are presented separately for adverse events.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TrtA -- TrtB -- TrtD -- TrtE</title>
          <description>Dabigatran 150mg (Trt. A), followed by Dabigatran 150mg + Dronedarone 400mg given simultaneously (Trt. B), followed by Dabigatran 150mg + Dronedarone 400mg bid given simultaneously (Trt. D), followed by Dabigatran 150mg + Dronedarone 400mg bid given 2h later (Trt. E)</description>
        </group>
        <group group_id="P2">
          <title>TrtA -- TrtC -- TrtE -- TrtD</title>
          <description>Dabigatran 150mg (Trt. A), followed by Dabigatran 150mg + Dronedarone 400mg given 2h later (Trt. C), followed by Dabigatran 150mg + Dronedarone 400mg bid given 2h later (Trt. E), followed by Dabigatran 150mg + Dronedarone 400mg bid given simultaneously (Trt. D)</description>
        </group>
        <group group_id="P3">
          <title>TrtB -- TrtD -- TrtE -- TrtA</title>
          <description>Dabigatran 150mg + Dronedarone 400mg given simultaneously (Trt. B), followed by Dabigatran 150mg + Dronedarone 400mg bid given simultaneously (Trt. D), followed by Dabigatran 150mg + Dronedarone 400mg bid given 2h later (Trt. E), followed by Dabigatran 150mg (Trt. A)</description>
        </group>
        <group group_id="P4">
          <title>TrtC -- TrtE -- TrtD -- TrtA</title>
          <description>Dabigatran 150mg + Dronedarone 400mg given 2h later (Trt. C), followed by Dabigatran 150mg + Dronedarone 400mg bid given 2h later (Trt. E), followed by Dabigatran 150mg + Dronedarone 400mg bid given simultaneously (Trt. D), followed by Dabigatran 150mg (Trt. A)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9">Treatment A was followed by a washout period of at least 96 hours.</participants>
                <participants group_id="P2" count="9">Treatment A was followed by a washout period of at least 96 hours.</participants>
                <participants group_id="P3" count="9">No washout period. Treatment D followed directly after treatment B.</participants>
                <participants group_id="P4" count="8">No washout period.Treatment E followed directly after treatment C.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non-compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9">No washout phase after Period 2.</participants>
                <participants group_id="P2" count="8">No washout phase after Period 2.</participants>
                <participants group_id="P3" count="9">No washout phase after Period 2.</participants>
                <participants group_id="P4" count="8">No washout phase after Period 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9">No washout period. Treatment E followed directly after treatment D.</participants>
                <participants group_id="P2" count="8">No washout period. Treatment D followed directly after treatment E.</participants>
                <participants group_id="P3" count="9">The last dose of Dronedarone was followed by a washout period of at least 10 days.</participants>
                <participants group_id="P4" count="8">The last dose of Dronedarone was followed by a washout period of at least 10 days.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set contains of all subjects who were dispensed study medication and were documented to have taken at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>TrtA -- TrtB -- TrtD -- TrtE</title>
          <description>Dabigatran 150mg (Trt. A), followed by Dabigatran 150mg + Dronedarone 400mg given simultaneously (Trt. B), followed by Dabigatran 150mg + Dronedarone 400mg bid given simultaneously (Trt. D), followed by Dabigatran 150mg + Dronedarone 400mg bid given 2h later (Trt. E)</description>
        </group>
        <group group_id="B2">
          <title>TrtA -- TrtC -- TrtE -- TrtD</title>
          <description>Dabigatran 150mg (Trt. A), followed by Dabigatran 150mg + Dronedarone 400mg given 2h later (Trt. C), followed by Dabigatran 150mg + Dronedarone 400mg bid given 2h later (Trt. E), followed by Dabigatran 150mg + Dronedarone 400mg bid given simultaneously (Trt. D)</description>
        </group>
        <group group_id="B3">
          <title>TrtB -- TrtD -- TrtE -- TrtA</title>
          <description>Dabigatran 150mg + Dronedarone 400mg given simultaneously (Trt. B), followed by Dabigatran 150mg + Dronedarone 400mg bid given simultaneously (Trt. D), followed by Dabigatran 150mg + Dronedarone 400mg bid given 2h later (Trt. E), followed by Dabigatran 150mg (Trt. A)</description>
        </group>
        <group group_id="B4">
          <title>TrtC -- TrtE -- TrtD -- TrtA</title>
          <description>Dabigatran 150mg + Dronedarone 400mg given 2h later (Trt. C), followed by Dabigatran 150mg + Dronedarone 400mg bid given 2h later (Trt. E), followed by Dabigatran 150mg + Dronedarone 400mg bid given simultaneously (Trt. D), followed by Dabigatran 150mg (Trt. A)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="10.7"/>
                    <measurement group_id="B2" value="37.8" spread="10.4"/>
                    <measurement group_id="B3" value="38.1" spread="9.7"/>
                    <measurement group_id="B4" value="33.3" spread="7.9"/>
                    <measurement group_id="B5" value="35.4" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
        <description>Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity.</description>
        <time_frame>1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set defined as all subjects randomised, treated and who provided evaluable data for at least one observation for at least one primary endpoint without important protocol violations relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>150mg DE (TrtA)</title>
            <description>Dabigatran 150mg</description>
          </group>
          <group group_id="O2">
            <title>150mg DE + 400mg DR (TrtB)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg given simultaneously</description>
          </group>
          <group group_id="O3">
            <title>150mg DE + 400mg DR 2h Later (TrtC)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg given 2h later</description>
          </group>
          <group group_id="O4">
            <title>150mg DE + 400mg DR Bid Same Time (TrtD)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg bid given simultaneously</description>
          </group>
          <group group_id="O5">
            <title>150mg DE + 400mg DR Bid 2h Later (TrtE)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg bid given 2h later</description>
          </group>
        </group_list>
        <measure>
          <title>Total Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
          <description>Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity.</description>
          <population>Pharmacokinetic (PK) set defined as all subjects randomised, treated and who provided evaluable data for at least one observation for at least one primary endpoint without important protocol violations relevant to the evaluation of PK.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1160" spread="40.3"/>
                    <measurement group_id="O2" value="2520" spread="27.1"/>
                    <measurement group_id="O3" value="1440" spread="40.3"/>
                    <measurement group_id="O4" value="2570" spread="28.1"/>
                    <measurement group_id="O5" value="1510" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR same time (TrtB) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>1.0000</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtB: TrtA (%)</param_type>
            <param_value>214</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>19.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>191</ci_lower_limit>
            <ci_upper_limit>240</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR 2h later (TrtC) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>0.6697</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtC: TrtA (%)</param_type>
            <param_value>130</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>25.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>112</ci_lower_limit>
            <ci_upper_limit>151</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR bid same time (TrtD) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>0.9992</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtD: TrtA (%)</param_type>
            <param_value>236</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>21.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>173</ci_lower_limit>
            <ci_upper_limit>321</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR bid 2h later (TrtE) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>0.9171</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtE: TrtA (%)</param_type>
            <param_value>162</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>20.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>119</ci_lower_limit>
            <ci_upper_limit>221</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Dabigatran: Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of total dabigatran in plasma, per period.</description>
        <time_frame>1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
        <population>PK set.</population>
        <group_list>
          <group group_id="O1">
            <title>150mg DE (TrtA)</title>
            <description>Dabigatran 150mg</description>
          </group>
          <group group_id="O2">
            <title>150mg DE + 400mg DR (TrtB)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg given simultaneously</description>
          </group>
          <group group_id="O3">
            <title>150mg DE + 400mg DR 2h Later (TrtC)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg given 2h later</description>
          </group>
          <group group_id="O4">
            <title>150mg DE + 400mg DR Bid Same Time (TrtD)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg bid given simultaneously</description>
          </group>
          <group group_id="O5">
            <title>150mg DE + 400mg DR Bid 2h Later (TrtE)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg bid given 2h later</description>
          </group>
        </group_list>
        <measure>
          <title>Total Dabigatran: Maximum Measured Concentration (Cmax)</title>
          <description>Maximum measured concentration of total dabigatran in plasma, per period.</description>
          <population>PK set.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149" spread="46.0"/>
                    <measurement group_id="O2" value="282" spread="30.1"/>
                    <measurement group_id="O3" value="166" spread="37.5"/>
                    <measurement group_id="O4" value="288" spread="29.9"/>
                    <measurement group_id="O5" value="163" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR (TrtB) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>0.9999</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtB: TrtA (%)</param_type>
            <param_value>187</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>162</ci_lower_limit>
            <ci_upper_limit>215</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR 2h later (TrtC) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>0.2207</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtC: TrtA (%)</param_type>
            <param_value>115</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>31.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95</ci_lower_limit>
            <ci_upper_limit>138</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR bid same time (TrtD) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>0.9946</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtD: TrtA (%)</param_type>
            <param_value>225</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>26.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>156</ci_lower_limit>
            <ci_upper_limit>326</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR bid 2h later (TrtE) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>0.6221</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtE: TrtA (%)</param_type>
            <param_value>133</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>23.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94</ci_lower_limit>
            <ci_upper_limit>190</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
        <description>Area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity.</description>
        <time_frame>1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
        <population>PK set.</population>
        <group_list>
          <group group_id="O1">
            <title>150mg DE (TrtA)</title>
            <description>Dabigatran 150mg</description>
          </group>
          <group group_id="O2">
            <title>150mg DE + 400mg DR (TrtB)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg given simultaneously</description>
          </group>
          <group group_id="O3">
            <title>150mg DE + 400mg DR 2h Later (TrtC)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg given 2h later</description>
          </group>
          <group group_id="O4">
            <title>150mg DE + 400mg DR Bid Same Time (TrtD)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg bid given simultaneously</description>
          </group>
          <group group_id="O5">
            <title>150mg DE + 400mg DR Bid 2h Later (TrtE)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg bid given 2h later</description>
          </group>
        </group_list>
        <measure>
          <title>Free Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
          <description>Area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity.</description>
          <population>PK set.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="919" spread="47.5"/>
                    <measurement group_id="O2" value="2110" spread="27.4"/>
                    <measurement group_id="O3" value="1110" spread="47.2"/>
                    <measurement group_id="O4" value="2100" spread="30.5"/>
                    <measurement group_id="O5" value="1260" spread="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR (TrtB) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>1.0000</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtB: TrtA (%)</param_type>
            <param_value>214</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>20.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>190</ci_lower_limit>
            <ci_upper_limit>241</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR 2h later (TrtC) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>0.7223</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtC: TrtA (%)</param_type>
            <param_value>132</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>26.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>113</ci_lower_limit>
            <ci_upper_limit>155</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR bid same time (TrtD) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>0.9993</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtD: TrtA (%)</param_type>
            <param_value>258</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>182</ci_lower_limit>
            <ci_upper_limit>365</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR bid 2h later (TrtE) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>0.8875</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtE: TrtA (%)</param_type>
            <param_value>159</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>21.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>114</ci_lower_limit>
            <ci_upper_limit>222</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free Dabigatran: Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of free dabigatran in plasma, per period.</description>
        <time_frame>1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration</time_frame>
        <population>PK set.</population>
        <group_list>
          <group group_id="O1">
            <title>150mg DE (TrtA)</title>
            <description>Dabigatran 150mg</description>
          </group>
          <group group_id="O2">
            <title>150mg DE + 400mg DR (TrtB)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg given simultaneously</description>
          </group>
          <group group_id="O3">
            <title>150mg DE + 400mg DR 2h Later (TrtC)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg given 2h later</description>
          </group>
          <group group_id="O4">
            <title>150mg DE + 400mg DR Bid Same Time (TrtD)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg bid given simultaneously</description>
          </group>
          <group group_id="O5">
            <title>150mg DE + 400mg DR Bid 2h Later (TrtE)</title>
            <description>Dabigatran 150mg + Dronedarone 400mg bid given 2h later</description>
          </group>
        </group_list>
        <measure>
          <title>Free Dabigatran: Maximum Measured Concentration (Cmax)</title>
          <description>Maximum measured concentration of free dabigatran in plasma, per period.</description>
          <population>PK set.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" spread="48.0"/>
                    <measurement group_id="O2" value="239" spread="27.6"/>
                    <measurement group_id="O3" value="133" spread="40.7"/>
                    <measurement group_id="O4" value="241" spread="29.5"/>
                    <measurement group_id="O5" value="138" spread="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR (TrtB) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>0.9998</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtB: TrtA (%)</param_type>
            <param_value>180</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>156</ci_lower_limit>
            <ci_upper_limit>207</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR 2h later (TrtC) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>0.1866</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtC: TrtA (%)</param_type>
            <param_value>114</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>29.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95</ci_lower_limit>
            <ci_upper_limit>136</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR bid same time (TrtD) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>0.9958</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtD: TrtA (%)</param_type>
            <param_value>234</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>26.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>160</ci_lower_limit>
            <ci_upper_limit>340</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>150mg DE + 400mg DR bid 2h later (TrtE) vs 150mg DE (TrtA)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioavailability</non_inferiority_desc>
            <p_value>0.5164</p_value>
            <p_value_desc>p-value for geometric mean ratio being outside interval 80% to 125%</p_value_desc>
            <method>ANOVA</method>
            <method_desc>ANOVA with sequence, period and treatment as fixed effects and subject within sequence as random effect.</method_desc>
            <param_type>Geometric mean ratio TrtE: TrtA (%)</param_type>
            <param_value>126</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>22.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89</ci_lower_limit>
            <ci_upper_limit>179</ci_upper_limit>
            <estimate_desc>The standard deviation is actually the Geometric coefficient of variation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>150mg DE (TrtA)</title>
          <description>Dabigatran 150mg</description>
        </group>
        <group group_id="E2">
          <title>150mg DE + 400mg DR (TrtB)</title>
          <description>Dabigatran 150mg + Dronedarone 400mg given simultaneously</description>
        </group>
        <group group_id="E3">
          <title>150mg DE + 400mg DR 2h Later (TrtC)</title>
          <description>Dabigatran 150mg + Dronedarone 400mg given 2h later</description>
        </group>
        <group group_id="E4">
          <title>150mg DE + 400mg DR Bid Same Time (TrtD)</title>
          <description>Dabigatran 150mg + Dronedarone 400mg bid given simultaneously</description>
        </group>
        <group group_id="E5">
          <title>150mg DE + 400mg DR Bid 2h Later (TrtE)</title>
          <description>Dabigatran 150mg + Dronedarone 400mg bid given 2h later</description>
        </group>
        <group group_id="E6">
          <title>400mg DR + 400mg DR Bid 2h Later (TrtE2)</title>
          <description>Dronedarone 400mg + Dronedarone 400mg bid given 2h later</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Listless</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

